{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:18Z","timestamp":1787721618676,"version":"build-2784847793"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BC) is the most common malignant tumor among women worldwide. ULBP1 (UL16 binding protein 1), as a ligand of NKG2D, has been associated with poor prognosis in multiple cancers; however, its role in BC remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TCGA and GEO datasets (TCGA-BRCA, GSE36295, and GSE1379) were used to evaluate the expression characteristics of ULBP1 and its association with prognosis. Functional enrichment analyses were subsequently performed to identify key biological pathways. The CIBERSORT and oncoPredict algorithms were applied to assess immune infiltration features and differences in drug sensitivity, respectively. In addition, qRT-PCR, western blotting, as well as CCK-8 and Transwell assays were conducted to validate ULBP1 expression in BC cells and to examine its effects on cellular functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analysis of public datasets revealed that ULBP1 is significantly overexpressed in BC tissues, and its high expression was independently associated with shortened overall survival. GSEA revealed that high ULBP1 expression was significantly enriched in immune-related pathways, including natural killer cell\u2013mediated cytotoxicity. Immune infiltration analysis indicated that high ULBP1 expression was closely associated with neutrophil enrichment and the upregulation of multiple immune checkpoint genes. Drug sensitivity prediction showed that patients with high ULBP1 expression may be more sensitive to olaparib and other agents.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments further confirmed that ULBP1 was highly expressed in BC cell lines, and that knockdown of ULBP1 significantly suppressed MCF-7 cell viability and reduced migratory and invasive capacities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ULBP1 may serve as a potential novel prognostic biomarker in BC, and targeting ULBP1 may provide a new therapeutic strategy for BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1788245","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:46:52Z","timestamp":1787719612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ULBP1 is a prognostic biomarker associated with immune suppression in breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Qixin","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]},{"name":"Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Medical University, Key Laboratory of Breast Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-06982-4","article-title":"LncRNA HOTAIR as a ceRNA is related to breast cancer risk and prognosis","volume":"200","author":"Qian","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2026.101281","article-title":"Integrating single-cell and spatial transcriptomics to dissect mast-cell heterogeneity and arginine-metabolism-associated markers in BRCA","volume":"73","author":"Gao","year":"2026","journal-title":"Neoplasia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/genes13060960","article-title":"The history of early breast cancer treatment","volume":"13","author":"Ben-Dror","year":"2022","journal-title":"Genes (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2020.5771","article-title":"lncRNA HOTAIR promotes DNA repair and radioresistance of breast cancer via EZH2","volume":"39","author":"Qian","year":"2020","journal-title":"DNA Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08474","article-title":"A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells","volume":"4","author":"Gowen","year":"2015","journal-title":"Elife"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-24","article-title":"NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study","volume":"12","author":"de Kruijf","year":"2012","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.158","article-title":"Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer","volume":"8","author":"Shen","year":"2017","journal-title":"Cell Death Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.762514","article-title":"Immune ULBP1 is elevated in colon adenocarcinoma and predicts prognosis","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00971","article-title":"ULBP1 is elevated in human hepatocellular carcinoma and predicts outcome","volume":"10","author":"Easom","year":"2020","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3390\/cancers16162852","article-title":"Temozolomide and the PARP inhibitor niraparib enhance expression of natural killer group 2D ligand ULBP1 and gamma-delta T cell cytotoxicity in glioblastoma","volume":"16","author":"Jones","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ol.2024.14761","article-title":"UL16-binding protein 1 is a significant prognostic and diagnostic marker for breast cancer","volume":"29","author":"Zhang","year":"2025","journal-title":"Oncol Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102532","article-title":"Integrated transcriptome and single-cell RNA sequencing analysis revealed the prognostic significance of GBP4 in pancreatic adenocarcinoma","volume":"61","author":"Chi","year":"2025","journal-title":"Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102584","article-title":"Development of multiple cell death pattern features to predict prognosis and drug sensitivity in gastric adenocarcinoma","volume":"63","author":"Yang","year":"2026","journal-title":"Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief Bioinform"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5802\/crchim.247","article-title":"Quantitative analysis of the effect of microtubule-targeting drugs on the microtubule cytoskeleton of breast cancer cells with different invasive properties","volume":"26","author":"Michallet","year":"2023","journal-title":"CR Chim"},{"key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3892\/ol.2023.13935","article-title":"Natural products as drug candidates for breast cancer (Review)","volume":"26","author":"Telang","year":"2023","journal-title":"Oncol Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-3110","article-title":"Honokiol inhibits the growth of SKBR3 cells","volume":"9","author":"Shi","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102586","article-title":"Unveiling shared PANoptosis mechanisms in LUAD and osteoarthritis via bioinformatics and machine learning","volume":"63","author":"Xiong","year":"2026","journal-title":"Transl Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2026.101288","article-title":"SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment","volume":"73","author":"Yang","year":"2026","journal-title":"Neoplasia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-025-01679-6","article-title":"The PARP inhibitor olaparib promotes senescence in murine macrophages","volume":"48","author":"Kieronska-Rudek","year":"2026","journal-title":"Geroscience"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608849","article-title":"NK cell interaction with platelets and myeloid cells in the tumor milieu","volume":"11","author":"Maurer","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3892\/ol.2020.12142","article-title":"Celecoxib upregulates ULBP-1 expression in lung cancer cells via the JNK\/PI3K signaling pathway and increases susceptibility to natural killer cell cytotoxicity","volume":"20","author":"Kim","year":"2020","journal-title":"Oncol Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13156","DOI":"10.3390\/ijms241713156","article-title":"Targeting NKG2DL with bispecific NKG2D-CD16 and NKG2D-CD3 fusion proteins on triple-negative breast cancer","volume":"24","author":"Kaidun","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.3390\/ijms25074126","article-title":"Soluble NKG2DLs are elevated in breast cancer patients and associate with disease outcome","volume":"25","author":"Seller","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12072","article-title":"Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications","volume":"78","author":"Chitadze","year":"2013","journal-title":"Scand J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16022","article-title":"Neutrophils in cancer, a love-hate affair","volume":"289","author":"Cerezo-Wallis","year":"2022","journal-title":"FEBS J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002573","article-title":"Ovarian mucinous neoplasms associated with mesonephric-like lesions: an updated study with novel pathologic features","author":"Smith","year":"2026","journal-title":"Am J Surg Pathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.2.6","article-title":"Olaparib: a novel therapy for metastatic breast cancer in patients with a BRCA1\/2 mutation","volume":"10","author":"Caulfield","year":"2019","journal-title":"J Adv Pract Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1788245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:46:58Z","timestamp":1787719618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1788245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1788245"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1788245","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1788245"}}